Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 27967875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)

  2015cites this paper
• Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

  2014cites this paper
• Challenges in the sequencing of therapies for the management of metastatic castration‐resistant prostate cancer

  2014cites this paper
• Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program

  2014cites this paper
• Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223

  2014cites this paper
• Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer

  2013cites this paper
• Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint

  2013cites this paper
• Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice.

  2013cites this paper
• Cabazitaxel in metastatic castration-resistant prostate cancer

  2012cites this paper